Abstract: An automatic cell isolation and collection system for sorting out target cells from a sample includes a crush module, a centrifuge module, a transport module, and a control unit. The centrifuge module includes centrifuge tubes and a magnetic mechanism providing a magnetically attractive force to at least one of the centrifuge tubes. The control unit electrically communicates with the crush module, the centrifuge module, and the transport module, and controls operation of the crush module, transport of the sample via the transport module after the sample is crushed by the crush module, centrifugation of the centrifuge module, and operation of the magnetic mechanism for providing the magnetically attractive force.

Abstract: Disclosed are: a lactic acid bacterium belonging to Lactobacillus kunkeei, the bacterium having a higher IgA production inducing activity than that of Lactobacillus strain GG (ATCC53103), and a lower mitogenic activity and a lower IL-2 production inducing activity than those of Listeria strain EGD; and a food composition, a pharmaceutical composition, a cosmetic composition, an immunostimulant for preventing the infection by pathogens or viruses that invade through the respiratory or esophageal mucosa, and an intestinal immunostimulant for preventing or alleviating food poisoning, each of which contains the lactic acid bacterium or treated cells of the lactic acid bacterium.

Abstract: Provided herein are seed train processes and methods of producing a recombinant protein that include the use of these seed train processes.

Abstract: The present invention provides a primary cell culture which combines a cell culture medium and cells derived from a hypertrophied androgenic gland (AG) of a decapod crustacean. The invention also provides methods for obtaining an all-female progeny by initially injecting/transplanting the primary cell culture to a genetic-female to obtain a male-Neo-male.

Abstract: The present invention provides a new readily accessible source of adult somatic stem cells from the gastrointestinal tract in general and oral mucosa in particular, methods for isolating pluripotent stem cells from oral mucosa, cells derived therefrom and uses thereof.

Abstract: Provided are a method of preparing retinal ganglion cells by differentiation of stem into retinal ganglion cells, retinal ganglion cells differentiated by the method, a method of screening for a death inhibitor or a proliferation promoter of retinal ganglion cells using the retinal ganglion cells differentiated by the method, a kit of screening for the death inhibitor or the proliferation promoter of retinal ganglion cells including the retinal ganglion cells differentiated by the method, a pharmaceutical composition for treating glaucoma or optic neuropathy including the retinal ganglion cells, a method of treating glaucoma or optic neuropathy including the step of administering the retinal ganglion cells to a subject suspected of having glaucoma or optic neuropathy, and a method of preparing a mature retinal ganglion cell line.

Abstract: Provided is a method for isolating and proliferating autologous cancer antigen-specific CD8+ T cells, and more particularly, a method for selecting an epitope recognized by CD8+ T cells from autologous cancer antigens present in blood of individual cancer patients; and isolating autologous cancer antigen-specific CD8+ T cells by using a peptide of the selected epitope, and a method of massively proliferating CD8+ T cells by using the method. According to the present invention, it is possible to isolate autologous cancer antigen-specific CD8+ T cells by using the peptide of the CD8 T cell epitope of the autologous cancer antigen present in blood of individual cancer patients instead of a heterologous antigen. Therefore, by using T cells recognizing the autologous cancer antigen, it is possible to effectively select and eliminate cancer cells derived from the cancer patient's own cells. Thus, T cells can be applied to treatment and alleviation of cancer diseases without side effects.

Abstract: The present invention provides a method for producing platelets, and the method comprises a step of culturing megakaryocytes in a culture solution in a culture vessel, wherein the culture solution is stirred with a stirrer in the culture step.

Abstract: Provided herein are methods of isolation and identification of post-natal hemogenic endothelial cells. Further provided are substantially purified populations of post-natal hemogenic endothelial cells, compositions of post-natal hemogenic endothelial cells, and methods to utilize hemogenic endothelial cells to regenerate the hematopoietic system in a subject.

Abstract: The present invention provides for methods of isolating a stem cell or cell derived therefrom from a mixture of cells, for example, a mixture of adherent cells in culture. Cell isolation is achieved by the application of selective detachment forces.

Abstract: The present invention provides for methods of isolating a stem cell or cell derived therefrom from a mixture of cells, for example, a mixture of adherent cells in culture. Cell isolation is achieved by the application of selective detachment forces.

Abstract: A process for the purification of influenza virus or derivative thereof requires providing a source of influenza virus or derivative thereof, optionally subjecting the source to a pre-purification step, followed by subjecting the source to at least one chromatographic step on chromatographic material selected from the group consisting of porous particles having mean pore sizes of at least 20 nm, perfusion particles, gel-in-a-shell particles, tentacle like particles, membrane adsorbers, and monoliths, and collecting fractions eluted from the chromatographic material that contain the influenza virus or derivative thereof, excluding sulfuric ester of cellulose or cross-linked polysaccharides.

Abstract: The present invention relates to an oncolytic virus which is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and/or at a lower dose in vitro than one or more of the other clinical isolates in the panel.

Abstract: The present disclosure provides compositions and methods for acetylating histones at targeted chromosomal locations in a cell. In particular, the disclosure provides a fusion protein comprising a DNA binding domain and at least one histone acetyltransferase (HAT) domain, such that the DNA binding domain targets the fusion protein to a targeted chromosomal location and the HAT domain acetylates histones at the targeted location.

Abstract: This document describes polypeptides with dual CoA transferase and ?-ketothiolase activities and variants thereof, use of such polypeptides in biosynthetic methods, and non-naturally occurring hosts comprising such polypeptides.

Abstract: The invention relates to the field of downstream processing (DSP) of an alkaline phosphatase (AP). More specifically, it relates to a method for reducing host cell protein content in a composition comprising AP. The invention further relates to a composition comprising an AP and a reduced content of a host cell protein.

Abstract: A novel peptide sequence that is a modified derivative of a neuron-specific tyrosine phosphatase is shown and described. Specifically, the novel peptide sequence is a modified derivative of striatal-enriched tyrosine phosphatase (STEP). The peptide sequence has been modified so as to be able to ameliorate and treat brain injury resulting from excessive glutamate release and/or oxidative stress. Examples of the types of brain injury which the presently disclosed peptide sequence is useful for treating includes acute brain injury resulting from stroke or traumatic brain injury and chronic disorders such as Huntington's chorea and schizophrenia. Furthermore, the presently described peptide sequence may further be useful in the treatment and amelioration of disorders associated with fear memory such as post-traumatic stress disorder.

Abstract: Transposase polypeptides and polynucleotides are provided, which have a high activity in mammalian cells. Methods for engineering cells, such as chimeric antigen T-cells, with the transposes are also provided.

Abstract: The present invention relates to polypeptides having cellulase activity, in particular to variants derived from the 20K-cellulase enzyme. The invention discloses a number of amino acid residue positions important for the properties of the cellulase enzyme and thereby for the stability and/or performance thereof. The novel variants have improved stability compared to the parental cellulase. In particular, the novel variants have good performance in an antigreying application and excellent stability in the presence of a protease in several detergent compositions even in long-term experiments.

Abstract: The present invention relates to isolated polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: A non-enzymatic method is provided for binding a first nucleic acid chain to a second nucleic acid chain without introducing a sulfur atom into the combined nucleic acid chain, the method comprising reacting a first nucleic acid chain having a phosphorothioate group at the 3? or 5? terminus with a second nucleic acid chain having a hydroxyl group or an amino group at the 3? or 5? terminus in the presence of an electrophile that has a leaving group and is configured to leave the leaving group and bind to a sulfur atom of the phosphorothioate group of the first nucleic acid chain at the site to which the leaving group had been bound, and remove the sulfur atom from the phosphorothioate group of the first nucleic acid chain and a hydrogen atom from the hydroxyl group or from the amino group of the second nucleic acid chain via a nucleophilic substitution with an oxygen atom of the hydroxyl group or a nitrogen atom of the amino group of the second nucleic acid chain, and thereby form a bond between a phosphorus a

Abstract: Disclosed herein is a novel method for multisite saturation mutagenesis. Provided in the instant disclosure is a means of generating genetic diversity at each desired codon position within the coding sequence of a gene using a multi-oligonucleotide primer pool and Gibson assembly approach where a mutant DNA library can be cloned into a target vector.

Abstract: Methods and compositions for identifying antigens of human lymphocytes are provided herein.

Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the cap analogs.

Abstract: Compositions, devices, and methods for treating infections.

Abstract: The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.

Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

Abstract: The present disclosure relates to methods of treating a patient suffering from or at risk of developing an ocular disease, disorder or injury, and includes treatment regimens using a double-stranded RNA compound that down-regulates CASP2 expression, or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of modulatory polynucleotides.

Abstract: Cell death is induced and/or cell growth is suppressed for a cell having a mutation in the BRAF gene. A drug suppressing GST-? is comprised as an active ingredient.

Abstract: The invention relates a method for producing a stable recombinant protein, comprising growing a non-naturally occurring host cell in a culture medium to produce a recombinant protein, and making a composition comprising the recombinant protein and a polysorbate. The production of endogenous lipoprotein lipase by the host cell is reduced. The endogenous lipoprotein lipase is present in the composition in a small amount, and is capable of degrading the polysorbate. The invention also relates to the relevant host cells and compositions, and preparation thereof.

Abstract: Certain embodiments provide methods and compositions related to clinical management of cancer patients based on the expression level of TMCO3. Further embodiments involve methods and compositions related to treatment of cancer patients or patients determined to have an increased TMCO3 level relative to a control or a reference level that is normal or indicating favorable prognosis.

Abstract: Disclosed are a recombinant Corynebacterium glutamicum (C. glutamicum) for producing fucosyllactose which is transformed to express ?-1,2-fucosyltransferase, GDP-D-mannose-4,6-dehydratase (Gmd), GDP-L-fucose synthase (WcaG) and lactose permease (LacY), wherein the Corynebacterium glutamicum has phosphomannomutase and GTP-mannose-1-phosphate guanylyltransferase, and a method for producing fucosyllactose using the same. According to the recombinant Corynebacterium glutamicum and the method for producing fucosyllactose according to the present invention, with use of a GRAS Corynebacterium glutamicum strain, which is safer than conventional Escherichia coli, 2?-fucosyllactose can be produced at a high concentration while overcoming drawbacks of conventional methods associated with industrial inapplicability resulting from low production concentrations.

Abstract: A method of introducing a nucleic acid sequence into a cell is provided where the cell has impaired or inhibited or disrupted DnaG primase activity or impaired or inhibited or disrupted DnaB helicase activity, or larger or increased gaps or distance between Okazaki fragments or lowered or reduced frequency of Okazaki fragment initiation, or the cell has increased single stranded DNA (ssDNA) on the lagging strand of the replication fork including transforming the cell through recombination with a nucleic acid oligomer.

Abstract: The present disclosure relates to compositions and methods for destabilizing biofilms, altering biofilm 3D structure, and dispersing biofilms, in order to enhance biofilm cell removal and/or sensitivity to other agents (e.g., environmental or co-applied treatments). In particular, the present disclosure relates to the use of L-arginine in the removal and/or sensitization (e.g., to antimicrobials) of microorganisms in medical, industrial, domestic, or environmental applications, as well as treatment of bacterial infections (e.g., in biofilms).

Abstract: The present invention relates to the field of the production of transgenic plants through Agrobacterium-mediated transformation of cells of somatic embryogenic calli or embryogenic suspension cultures and regeneration of the transformed cells into fruit-setting plants. In particular, the present invention relates to the production of transgenic plants in the Euphorbiaceae family. The present invention further relates to media compositions, selection methods and engineered Agrobacterium tumefaciens strains that improve Agrobacterium-mediated transformation efficiency.

Abstract: This disclosure concerns compositions and methods for promoting transcription and translation of a nucleotide sequence in a plant or plant cell, employing a 3?UTR from Zea mays chlorophyll a/b binding protein gene. Some embodiments relate to a 3? UTR from a Zea mays chlorophyll a/b binding protein gene that functions in plants to terminate transcription of operably linked nucleotide sequences.

Abstract: The application describes stabilized WRINKLED1 transcription factors, as well as nucleic acids, and expression cassettes that encode and express such stabilized WRINKLED1 transcription factors and that are useful for increasing production of oils in plants and seeds.

Abstract: The present embodiments relate to elite event NS-B50027-4, seeds and oils obtained from NS-B50027-4, progeny derived from NS-B50027-4, the genetic and phenotypic characteristics of NS-B50027-4, and compositions and methods for the identification of elite event NS-B50027-4. In particular, NS-B50027-4 is a transgenic canola line capable of producing at least 5% DHA in its seed oil.

Abstract: Methods for obtaining soybean plants that produce seed with low linolenic acid levels and moderately increased oleic levels are disclosed. Also disclosed are methods for producing seed with low linolenic acid levels, moderately increased oleic levels and low saturated fatty acid levels. These methods entail the combination of transgenes that provide moderate oleic acid levels with soybean germplasm that contains mutations in soybean genes that confer low linolenic acid phenotypes. These methods also entail the combination of transgenes that provide both moderate oleic acid levels and low saturated fat levels with soybean germplasm that contains mutations in soybean genes that confer low linolenic acid phenotypes. Soybean plants and seeds produced by these methods are also disclosed.

Abstract: The invention relates to a method for producing a genetically modified woody plant with improved growth properties (in terms of biomass and/or wood density) as compared to a corresponding non-genetically modified wild type plant or woody plant, said method comprising altering the level of expression of a polypeptide in a woody plant cell; a woody plant; or a part thereof.

Abstract: This invention provides recombinant DNA constructs, transgenic plant nuclei and cells with such recombinant DNA construct for expression of proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants. This invention also provides transgenic plants and progeny seed comprising the transgenic plant cells where the plants are selected for having an enhanced trait selected from the group of traits consisting of enhanced water use efficiency, enhanced cold tolerance, increased yield, enhanced nitrogen use efficiency, enhanced seed protein and enhanced seed oil. Also disclosed are methods for manufacturing transgenic seed and plants with enhanced traits.

Abstract: Methods and compositions of improving plant yield by introducing into a plant the K-domain of a MADS box gene are disclosed. The expression of the K-domain provides plants with altered flower development, plant size and leaf development.

Abstract: This invention relates to an artificial salt tolerant protein NLEA with the amino acid sequence shown in SEQ ID No.1 and a synthetic method of salt tolerant protein NLEA comprising the steps of retrieving different types of LEA proteins from LEA database; making multiple sequence alignment on different types of LEA proteins to obtain conserved short peptides; selecting hydrophilic short peptides with a hydrophilicity index higher than 3.5 from conserved short peptides; arranging and splicing hydrophilic short peptides in the order of isoelectric point size from large to small, to obtain salt tolerant protein NLEA. This invention involves bioinformatics analysis by retrieving different LEA conserved amino acid sequences of LEA protein data. Physical properties are analyzed to find short peptides of high hydrophilicity, and such short peptides are arranged in the order of isoelectric point size and spliced to get a new hydrophilic amino acid sequence.

Abstract: The present invention is directed to wheat plants and triticale plants having increased tolerance to an imidazolinone herbicide. More particularly, the present invention includes wheat plants or triticale plants containing one or more Triticum turgidum IMI nucleic acids. The present invention also includes seeds produced by these wheat plants and triticale plants, and methods of controlling weeds in the vicinity of these wheat plants and triticale plants.

Abstract: A method for increasing fungal resistance in a plant, a plant part, or a plant cell wherein the method comprises the step of increasing the production and/or accumulation of scopoletin and/or a derivative thereof in the plant, plant part, or plant cell in comparison to a wild type plant, wild type plant part, or wild type plant cell.

Abstract: Trap and/or refuge crops and methods of use in managing corn rootworm and other insect pests of maize are provided. Some methods involve using trap crops comprising plants with enhanced susceptibility to one or more insect pests to lure and kill insect pests. Other methods involve using refuge crops comprising plants with enhanced susceptibility to one or more insect pests to monitor insect pest populations in an area or to promote mating between insecticide resistant and insecticide non-resistant insects.

Abstract: This invention provides plants having resistance to invertebrate pests. More specifically, this invention discloses a non-natural transgenic plant cell expressing at least one invertebrate miRNA in planta for suppression of a target gene of an invertebrate pest or of a symbiont associated with the invertebrate pest. Also provided are recombinant DNA constructs for expression of at least one invertebrate miRNA in planta, a non-natural transgenic plant containing the non-natural transgenic plant cell of this invention, a non-natural transgenic plant grown from the non-natural transgenic plant cell of this invention, and non-natural transgenic seed produced by the non-natural transgenic plants, as well as commodity products produced from a non-natural transgenic plant cell, plant, or seed of this invention.

Abstract: The present disclosure provides CasX proteins, nucleic acids encoding the CasX proteins, and modified host cells comprising the CasX proteins and/or nucleic acids encoding same. CasX proteins are useful in a variety of applications, which are provided. The present disclosure provides CasX guide RNAs that bind to and provide sequence specificity to the CasX proteins, nucleic acids encoding the CasX guide RNAs, and modified host cells comprising the CasX guide RNAs and/or nucleic acids encoding same. CasX guide RNAs are useful in a variety of applications, which are provided. The present disclosure provides archaeal Cas9 polypeptides and nucleic acids encoding same, as well as their associated archaeal Cas9 guide RNAs and nucleic acids encoding same.